Literature DB >> 14575768

Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost.

Su-Hyung Park1, Se-Hwan Yang, Chang Geun Lee, Jin-Won Youn, Jun Chang, Young Chul Sung.   

Abstract

Hepatitis C virus (HCV) is an important causative agent of liver disease, but currently there is no available prophylactic vaccine against HCV infection. Here, we investigated the HCV E2- and core-specific T-cell responses induced by DNA (D) and/or recombinant adenovirus (A) vaccines. In single (D versus A) or double immunizations (D-D versus A-A), the recombinant adenovirus vaccines induced higher levels of IFN-gamma secreting T-cell response and cytotoxic T lymphocytes (CTL) response than the DNA vaccines. However, a heterologous (D-A) regimen elicited the highest level of T helper 1 (Th1) CD4(+) T-cell responses. Furthermore, three E2-specific CTL epitopes were mapped using a peptide pool spanning the E2 protein sequence (a.a. 384-713) in BALB/c mice, and one of these (E2 405-414: SGPSQKIQLV) was shown to be immunodominant. Interestingly, no significant differences were found in the repertoire of E2-specific T-cell responses or in the immunodominance hierarchy of the three epitopes induced by D-D, D-A, A-A, and A-D, indicating that the breadth and hierarchy of T-cell responses is independent of these different vaccination regimens. In conclusion, the heterologous DNA prime-recombinant adenovirus boost regimen described offers an efficient promising strategy for the development of an effective T-cell-based HCV vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575768     DOI: 10.1016/s0264-410x(03)00499-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.

Authors:  Stefania Capone; Annalisa Meola; Bruno Bruni Ercole; Alessandra Vitelli; Monica Pezzanera; Lionello Ruggeri; Mary Ellen Davies; Rosalba Tafi; Claudia Santini; Alessandra Luzzago; Tong-Ming Fu; Andrew Bett; Stefano Colloca; Riccardo Cortese; Alfredo Nicosia; Antonella Folgori
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice.

Authors:  Atefeh Saeedi; Amir Ghaemi; Alijan Tabarraei; Abdolvahab Moradi; Ali Gorji; Shahryar Semnani; Hoorieh Soleimanjahi; Ahmad Hosseinzadeh Adli; Seyed Yones Hosseini; Mohammad Ali Vakili
Journal:  Virus Genes       Date:  2014-04-22       Impact factor: 2.332

3.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

Authors:  Pierre-Alexandre Bart; Yunda Huang; Shelly T Karuna; Samuel Chappuis; Julien Gaillard; Nidhi Kochar; Xiaoying Shen; Mary A Allen; Song Ding; John Hural; Hua-Xin Liao; Barton F Haynes; Barney S Graham; Peter B Gilbert; M Juliana McElrath; David C Montefiori; Georgia D Tomaras; Giuseppe Pantaleo; Nicole Frahm
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

5.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

6.  Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu.

Authors:  Zhidong Hu; Jing Wang; Yanmin Wan; Lingyan Zhu; Xiaonan Ren; Sugan Qiu; Yanqin Ren; Songhua Yuan; Xiangqing Ding; Jian Chen; Chenli Qiu; Jun Sun; Xiaoyan Zhang; Jim Xiang; Chao Qiu; Jianqing Xu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 7.  Heterologous prime-boost vaccination.

Authors:  Shan Lu
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

8.  Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Authors:  Jin-Won Youn; Yu-Wen Hu; Nancy Tricoche; Wolfram Pfahler; Mohamed Tarek Shata; Marlene Dreux; François-Loic Cosset; Antonella Folgori; Dong-Hun Lee; Betsy Brotman; Alfred M Prince
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

9.  Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys.

Authors:  Su-Hyung Park; Mi-Young Song; Hyo Jung Nam; Se Jin Im; Young-Chul Sung
Journal:  Immune Netw       Date:  2010-12-31       Impact factor: 6.303

10.  Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant.

Authors:  Man Li; Yuhong Jiang; Chaoqun Xu; Zhirong Zhang; Xun Sun
Journal:  Int J Nanomedicine       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.